Journal Article

Carbapenemase-producing bacteria in companion animals: a public health concern on the horizon

Sam Abraham, Hui San Wong, John Turnidge, James R. Johnson and Darren J. Trott

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 69, issue 5, pages 1155-1157
Published in print May 2014 | ISSN: 0305-7453
Published online January 2014 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dkt518
Carbapenemase-producing bacteria in companion animals: a public health concern on the horizon

Show Summary Details

Preview

Clinical infections attributed to carbapenemase-producing bacteria are a pressing public health concern owing to limited therapeutic options and linked antimicrobial resistance. In recent years, studies have reported the emergence and spread of carbapenemase-producing Enterobacteriaceae and their public health impact. This has been closely followed by the global dissemination of highly resistant and virulent zooanthroponotic extraintestinal pathogenic Escherichia coli (ExPEC) ST131 clones. It has also been hypothesized that companion animals may act as a reservoir for Gram-negative multidrug-resistant pathogens in the community. Two recent reports have documented the emergence of carbapenemase-producing bacteria in companion animals. This phenomenon is of great concern because of the close contact between humans and their pets, and the potential for cross-species transmission. This scenario suggests a role for multifaceted control of Gram-negative multidrug-resistant infections in companion animals. This short article addresses this issue and identifies steps that could facilitate this process.

Keywords: Escherichia coli; urinary tract infections; UTIs; antibiotic resistance; NDM-1; OXA-48; ST131

Journal Article.  1566 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.